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A B S T R A C T
STING has emerged in recent years as an important signalling adaptor in the activation of type I
interferon responses during infection with DNA viruses and bacteria. An increasing body of evidence
suggests that STING also modulates responses to RNA viruses, though the mechanisms remain less clear.
In this review, we give a brief overview of the ways in which STING facilitates sensing of RNA viruses.
These include modulation of RIG-I-dependent responses through STING’s interaction with MAVS, and
more speculative mechanisms involving the DNA sensor cGAS and sensing of membrane remodelling
events. We then provide an in-depth literature review to summarise the known mechanisms by which
RNA viruses of the families Flaviviridae and Coronaviridae evade sensing through STING. Our own work
has shown that the NS2B/3 protease complex of the ﬂavivirus dengue virus binds and cleaves STING, and
that an inability to degrade murine STING may contribute to host restriction in this virus. We contrast
this to the mechanism employed by the distantly related hepacivirus hepatitis C virus, in which STING is
bound and inactivated by the NS4B protein. Finally, we discuss STING antagonism in the coronaviruses
SARS coronavirus and human coronavirus NL63, which disrupt K63-linked polyubiquitination and
dimerisation of STING (both of which are required for STING-mediated activation of IRF-3) via their
papain-like proteases. We draw parallels with less-well characterised mechanisms of STING antagonism
in related viruses, and place our current knowledge in the context of species tropism restrictions that
potentially affect the emergence of new human pathogens.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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jo ur n al ho mep ag e: www .e lsev ier . c om / loc ate /c yto g f rThe production of the type I interferons (IFNs) IFN-a and IFN-b
is one of the most critical early events in the induction of an
antiviral innate immune response. Type I IFN is induced during
viral infection and signals in an autocrine and paracrine manner to
activate the transcription of a number of IFN-stimulated genes
(ISGs) that establish an antiviral state to limit the spread of theAbbreviations: BiFC, bimolecular ﬂuorescence complementation; CARD, caspase
activation and recruitment domain; cGAMP, cyclic GMP-AMP; cGAS, cyclic GMP-
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ISRE, interferon-stimulated response element; MAM, mitochondria-associated
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differentiation-associated gene 5; MDDC, monocyte-derived dendritic cell; mKG,
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pathogen-associated molecular patterns (PAMPs) by cellular
pattern recognition receptors (PRRs). The most well-characterised
PRRs relevant to RNA virus infection are retinoic acid-inducible
gene I (RIG-I) and melanoma differentiation-associated gene 5
(MDA-5). RIG-I and MDA-5 sense cytoplasmic viral double-
stranded RNA (dsRNA) replication intermediates and associate
with mitochondrial antiviral signalling protein (MAVS) (also
known as IFN-b promoter stimulator 1, IPS-1, virus-induced
signalling adapter, VISA, and CARD-adapter inducing IFN-b,
CARDIF) at the mitochondrial membrane to activate the transcrip-
tion factor IFN regulatory factor 3 (IRF-3) [reviewed in 1,2].
More recently, stimulator of interferon genes (STING) was
identiﬁed as a novel and important modulator of type I IFN
induction via IRF-3 [3–5]. STING is also sometimes referred to as
transmembrane protein 173 (TMEM173), mediator of IRF-3
activation (MITA), endoplasmic reticulum IFN stimulator (ERIS)
or MPYS (named after its four N-terminal amino acids). STING is
probably best known for its role in sensing bacteria and DNA
viruses [reviewed in 6,7]. However, it has become increasinglynder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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virus replication. The replication of diverse positive- and negative-
sense RNA viruses is enhanced in the absence of STING in in vivo, ex
vivo and in vitro models [3–5,8–10]. Furthermore, STING becomes
activated, and its expression is increased, during RNA virus
infection [4,5,9,11,12]. Finally, the fact that several RNA viruses
have been shown to antagonise STING implies that STING is an
important restriction factor during RNA virus infection [8–15].
STING is membrane-associated via its four N-terminal trans-
membrane domains, and within the cell STING is localised to the
endoplasmic reticulum (ER), with a partial localisation to
mitochondria and mitochondria-associated membranes (MAMs)
[3–5,8]. Following stimulation, STING dimerises and translocates
to punctate perinuclear vesicles, where it interacts with tank-
binding kinase 1 (TBK1) and IRF-3 (Fig. 1) [reviewed in 7]. The
subsequent phosphorylation of STING and IRF-3 by TBK1 leads toFig. 1. STING signalling during RNA virus infection. Inactive STING resides in membranes o
relocalises to perinuclear punctate domains, where it interacts with TBK1 to phosphor
polyubiquitination. Following its activation, IRF-3 dimerises and translocates to the nucle
viruses have been proposed to be sensed by three distinct mechanisms in relation to STING
the 50-triphosphates of uncapped viral RNAs are recognised by RIG-I, which associates w
linked to the sensing of positive-sense RNA viruses by an as-yet undeﬁned mechanism. I
virus infection, and cGAMP binds and activates STING. (3) Viral fusion events at the plas
involving PI(3)K and phospholipase C-g (PLC-g). For simplicity, only signalling molecuthe nuclear translocation of IRF-3 and the induction of type I IFN
and other cytokines [7]. The dimerisation and relocalisation of
STING is essential for the recruitment of TBK1 to these perinuclear
sites, as well as for the downstream activation of IRF-3 and type I
IFN production [5,7,16]. The interaction between STING and TBK1,
and possibly STING dimerisation, is promoted by K63-linked
polyubiquitination of STING at various residues by tripartite motif-
containing 32 (TRIM32) and TRIM56 [17,18]. STING can also induce
NF-kB signalling, though the mechanism remains to be fully
elucidated [7].
In order to establish a productive infection, successful viruses
must evade recognition by the innate immune system, and
antagonism of STING signalling has been identiﬁed in several
divergent positive-sense RNA viruses [8–15]. Curiously, to our
knowledge, STING antagonism has not yet been described for any
negative-sense RNA virus. In the remainder of this article, we willf the ER, MAM and mitochondria (M*). Following its activation, STING dimerises and
ylate IRF-3. Activated STING is also modiﬁed by phosphorylation and K63-linked
us, where it induces the transcription of the type I interferons IFN-a and IFN-b. RNA
 activation. (1) Viral dsRNA replication intermediates and stem-loop structures, and
ith MAVS and STING at MAMs to activate STING. (2) The DNA sensor cGAS has been
n this scenario, cGAS produces the messenger molecule cGAMP after detecting RNA
ma membrane have been shown to activate STING by a poorly-deﬁned mechanism
les referred to in the main text are shown.
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sensing of RNA viruses, and provide an in-depth review of the
known mechanisms RNA viruses use to evade STING signalling.
1. Every breath you take: how STING may sense multiple stages
of the RNA virus life cycle
STING is activated by several distinct mechanisms. For detailed
information on the mechanisms of STING activation in response to
DNA PAMPs, the reader is directed to two recent reviews by
Unterholzner, and Ran et al. [6,7]. Fig. 1 summarises the
mechanisms by which RNA virus infection is thought to activate
STING. While STING has been shown to directly bind DNA, it does
not interact with the dsRNA mimic poly(I:C) [19], suggesting that
STING itself does not function as a PRR for the recognition of RNA
virus PAMPs. However, STING has been shown to function as an
adapter in the sensing of RNA viruses via RIG-I [reviewed in
7]. STING interacts with RIG-I, but not MDA-5, and consequently
STING is activated by ligands that bind RIG-I, but not those
detected by MDA-5 [3,4,7]. MDA-5 senses long dsRNA molecules,
while RIG-I senses shorter dsRNA elements and the uncapped 50-
triphosphate of exogenous RNAs [reviewed in 20]. STING can also
be activated through the exogenous expression of a C-terminally
truncated RIG-I construct (DRIG-I) that is constitutively active
because it encodes only the N-terminal CARD signalling domains of
RIG-I [3,21]. Ultimately this results in STING participating in
immune responses mounted against RNA viruses sensed by RIG-I,
including Sendai virus (SeV), vesicular stomatitis virus (VSV),
Newcastle disease virus (NDV) and Japanese encephalitis virus
(JEV), but not those sensed exclusively by MDA-5 [7]. Following
activation via RIG-I, STING interacts with the adapter protein
MAVS at the MAM or mitochondria, and after its translocation to
perinuclear vesicles, STING then acts as a scaffold for the
recruitment of TBK1 and other signalling components required
for IRF-3 activation and type I IFN induction [3,4,7,8]. This role in
modulating RIG-I-dependent antiviral responses is likely one of the
major ways in which STING contributes to immune sensing of RNA
viruses. However, several recent reports suggest that there may be
additional RIG-I-independent ways by which STING helps sense
RNA virus infection [22–24].
Cyclic GMP-AMP synthase (cGAS) is a recently-discovered
cytosolic PRR that detects double-stranded DNA (dsDNA) and
produces the signalling molecule cyclic GMP-AMP (cGAMP), which
binds and activates STING during DNA virus infection [reviewed in
6,7]. Interestingly, in a recent screen for the antiviral activity of
known ISGs, Schoggins et al. identiﬁed cGAS as one of the most
potent restriction factors for all positive-sense RNA viruses tested
[22,23]. The antiviral effects of cGAS were still evident in the
absence of RIG-I [23]. Importantly, mortality and virus replication
were increased in cGAS knock-out mice infected with the positive-
sense RNA virus West Nile virus (WNV) [22]. Whether cGAS acts as
a bona ﬁde RNA sensor remains controversial. While, cGAS does not
bind poly(I:C) in vitro [6,7,25], a recent report showed that cGAS
was able to bind a synthetic 50mer dsRNA, although this did not
result on the generation of cGAMP [26]. Since cGAMP is required
for cGAS-mediated STING activation [6,7,25], it remains somewhat
mysterious how cGAS contributes to RNA virus sensing. Schoggins
et al. proposed that, because basal expression levels were reduced
for a subset of ISGs in the absence of cGAS, cGAS might modulate
the overall refractoriness of cells to RNA viruses [22]. Nevertheless,
negative-sense RNA viruses are not restricted by cGAS [22], and
this exquisite speciﬁcity of cGAS for positive-sense RNA viruses
suggests that cGAS might be directly involved in sensing positive-
sense RNA virus infection.
One of the characteristics shared by positive-sense RNA viruses
is that they modify cellular membranes to form cytoplasmicmembranous replication compartments required for viral RNA
synthesis [27]. Direct evidence that such membrane modiﬁcations
activate STING and/or cGAS is lacking. However, STING signalling
has been shown to be induced by fusion events at the plasma
membrane [24]. Both cationic liposomes and herpesvirus-derived
virus-like particles that lack nucleic acids were shown to cause the
relocalisation of STING to TBK1-containing perinuclear vesicles, as
well as the induction of cytokines in a manner that was dependent
upon STING, TBK1 and IRF-3 [24]. This activation of STING did not
require the RIG-I signalling pathway [24]. Instead, the fusion-
mediated activation of STING involved an as-yet poorly-char-
acterised mechanism involving phospholipase C-g and phospha-
tidylinositol-3-OH kinase (PI(3)K) [24]. Therefore, membrane-
remodelling events during viral entry or later on in the viral life
cycle may also be sensed by STING to induce STING activation. It is
interesting to speculate that STING might also sense other
disruptions to the normal cellular equilibrium, such as the release
of self-DNA into the cytoplasm or mitochondrial dysregulation
during infection with certain viruses.
Further work will be needed to clarify whether positive-sense
RNA viruses are detected by a multitude of mechanisms
converging on STING, including RIG-I-dependent sensing of
cytoplasmic viral RNA, fusion events during viral entry, poorly-
deﬁned sensing via cGAS, or a combination of these and other
potential mechanisms.
2. Don’t stand so close to me: how RNA viruses take the STING
out of innate immune recognition
Despite the fact that the role of STING in sensing of DNA viruses
is more clearly elucidated than for RNA viruses, the ﬁrst STING
antagonist was discovered in an RNA virus, the ﬂavivirus yellow
fever virus (YFV) [8]. Just one year after ﬁrst identifying STING, the
Barber group went on to show that the YFV non-structural protein
NS4B inhibits IFN-b induction by STING [8]. However, it was not
until several years later that the ﬁrst fully-characterised mecha-
nism of STING antagonism by a viral protein was described for the
coronavirus papain-like proteases (PLPs) [11], followed shortly
thereafter by the NS2B/3 protease complex from the ﬂavivirus
dengue virus (DENV) [9,12]. The remainder of this review will
focus on the known STING antagonists encoded by positive-sense
RNA viruses, from the families Flaviviridae and Coronaviridae, and
the mechanisms by which they counteract the STING signalling
pathway (summarised in Table 1).
2.1. Flaviviridae
The family Flaviviridae encompasses four genera, Flavivirus and
Hepacivirus (discussed here), and Pegivirus and Pestivirus (Fig. 2A)
[28]. Members of the family Flaviviridae are enveloped viruses
that encode a non-segmented positive-sense single-stranded RNA
(ssRNA) genome that lacks a poly(A) tail (Fig. 2B and C) [28].
Immediately upon entry into the cytoplasm, translation of the viral
genome produces a polyprotein that is proteolytically processed by
viral and cellular proteases to yield the structural and non-structural
(NS) proteins [28]. Viral replication occurs via a negative-sense RNA
intermediate in cytoplasmic membranous compartments derived
from the ER, with maturation and release of infectious viral progeny
proceeding through the secretory pathway [28].
We will begin by describing the STING antagonists encoded by
the genus Flavivirus, the human pathogens of which are all
arthropod-borne viruses (arboviruses) transmitted by mosquitoes
or ticks [29]. Flaviviruses pathogenic to humans include DENV, JEV,
WNV, YFV and the tick-borne encephalitis virus (TBEV) complex.
All of these ﬂaviviruses cause potentially severe disease in humans,
and many are considered emerging or re-emerging pathogens [30].
Table 1
Mechanisms of STING antagonism by positive-sense RNA viruses.
Family Genus Species Protein Mechanism of STING Antagonism References
Flaviviridae Flavivirus DENV NS2B/3 Binds and cleaves hSTING, but not mSTING, inactivating STING
function. Transgenic mice expressing hSTING might be improved
animal models for DENV pathogenesis. Protease activity is
essential and sufﬁcient.
[9,12,39]
YFV NS4B Unknown [8]
Hepacivirus HCV NS4B Binds STING at MAMs via N-terminal STING-homology domain.
May disrupt STING signalling complexes. Acts independently of
NS3/4A-dependent MAVS antagonism.
[10,13,57,58]
Coronaviridae Alphacoronavirus HCoV-NL63 PLP2 Binds STING to disrupt K63-linked polyubiquitination and
dimerisation of STING, and formation of multicomponent signalling
complexes. Protease activity not required.
[11,71]
PEDV PLP2 Binds STING and disrupts K63-linked polyubiquitination of STING.
DUB activity essential?a
[15]
Betacoronavirus SARS-CoV PLpro Binds STING to disrupt K63-linked polyubiquitination and
dimerisation of STING, and formation of multicomponent
signalling complexes. Protease activity not required.
[11,14,70,71]
a The role of DUB activity in STING antagonism by coronavirus PLPs remains controversial and may be affected by the presence of the transmembrane domain.
Fig. 2. Flaviviridae phylogenetic tree and genome organisation. (A) Flaviviridae family tree. Viruses of relevance to this review, and other representative viruses, shown. (B)
Mosquito-borne ﬂavivirus (11 kb) and (C) hepacivirus (9.6 kb) genome organisation (not to scale). Structural proteins are in black. STING antagonists are highlighted in
grey. A STING antagonist function has been described for the YFV NS4B protein, but not for the DENV NS4B. Additional known functions for proteins discussed in this review
are also given. Triangles indicate cleavage sites for the ﬂavivirus NS2B/3 (B) or hepacivirus NS3/4A (C) proteases. The HCV polyuridine tract ((U/UC)n) is a well-known PAMP
that induces type I IFN production. Note that the hepacivirus genome is uncapped. Members of the Flaviviridae lack a poly(A) tail. Viruses not deﬁned elsewhere; CSFV,
classical swine fever virus; BDV, bovine diarrhoea virus; GBV, GV virus.
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currently approved, and there are no licensed speciﬁc antiviral
therapies available [30,31].
2.1.1. Every little thing she does is magic: STING antagonism by the
dengue virus NS2B/3 protease complex
Of the ﬂaviviruses, the mechanism of STING antagonism has
been studied in most detail for DENV, which is also the focus of
research in our lab. DENV is arguable the most signiﬁcant arboviral
pathogen of humans with up to 2.5 billion people at risk of
infection in the tropics and subtropics, and an estimated 50 million
cases of dengue fever and the more severe dengue haemorrhagic
fever annually, resulting in over 20,000 deaths [29,30,32,33]. The
ways in which DENV evades STING signalling is of particular
interest because the dysregulated production of cytokines and
chemokines during DENV infection is known to contribute to
symptoms associated with severe dengue disease [29,34]. Further-
more, developing a DENV vaccine has so far proven challenging
[35,36], and understanding how DENV modulates the immune
response may lead to improved vaccine strategies.
In vivo, DENV replicates predominantly in myeloid cells,
including monocytes, dendritic cells (DCs) and macrophages
[29,37]. We were the ﬁrst to show that DENV fails to induce a
robust IFN response in primary human monocyte-derived DCs
(MDDCs), despite the fact that the production of other pro-
inﬂammatory cytokines and chemokines is unimpaired [38]. Type I
IFN is also poorly induced in DENV-infected plasmacytoid and
blood-circulating DCs, B cells, monocytes and in whole peripheral
blood mononuclear cells (PBMCs) [9]. Furthermore, DENV-infected
MDDCs failed to induce Th1 responses in allogeneic T-cells [38],
suggesting that inappropriate activation of DCs may have down-
stream consequences for adaptive immune responses mounted
during DENV infection.
We later went on to identify the viral protease, consisting of the
non-structural proteins NS3 and its cofactor NS2B, which together
are also responsible for cleaving the viral polyprotein [29], as an
antagonist of type-I IFN production [39]. Speciﬁcally, we
demonstrated that the NS2B/3 protease complex inhibited
activation of a luciferase reporter controlled by the IFN-b
promoter in 293T cells stimulated with poly(I:C) or after infection
with SeV [39]. We veriﬁed these ﬁndings by measuring endoge-
nous IFN-a production in MDDCs infected with an NDV mutant
expressing the DENV NS2B/3 protein. This NDV virus exhibited
impaired IFN-a induction relative to its parental wild-type (wt)
[39]. Yu et al. later showed that NS2B/3 inhibits type I IFN
induction above the level of IRF-3 phosphorylation [12], which we
had also observed during DENV infection in MDDCs [39]. In
addition to its protease activity, NS3 by itself also functions as a
helicase, NTPase and 50 triphosphatase during viral RNA replica-
tion [29]. We were able to distinguish between these diverse
functions of NS3 by showing that a construct encoding a truncated
NS3 containing only its proteolytic core, as well as the minimal
NS2B accessory region, was just as efﬁcient at inhibiting IFN-b
promoter activation as wt NS2B/3 [39]. Importantly, we also
conﬁrmed that a proteolytically-inactive NS2B/3 mutant harbour-
ing a serine-to-alanine mutation at position 135 (S135A) did not
inhibit type I IFN induction [39].
In 2012, IFN antagonism by the DENV NS2B/3 protease was
linked to its ability to bind and cleave STING in two concurrent
papers originating from our lab and that of Yi-Ling Lin [9,12]. The
stories presented by both groups are broadly in agreement of each
other. While our work characterised the mechanism of STING
antagonism by NS2B/3 in primary human MDDCs [9], highly
relevant to DENV infection in vivo, work by the Lin group provided
additional mechanistic insights into the fate of STING after its
cleavage by NS2B/3 [12].STING was shown to interact with both wt NS2B/3 and the
catalytically inactive S135A mutant in over-expression experi-
ments [9,12]. Furthermore, wt NS2B/3 expressed exogenously or in
the context of DENV infection rapidly degraded endogenous and
over-expressed STING, by 24 h post-infection (hpi) in tissue
culture and in MDDCs infected at high multiplicity with DENV
[9,12]. Catalytically inactive NS2B/3 did not degrade STING
[9,12]. The Lin group also reported that STING and NS2B/3
colocalise when over-expressed in A549 cells, and that STING-
NS2B/3 binding, colocalisation and cleavage is enhanced when
STING signalling is stimulated with a dsDNA PAMP such as
poly(dA:dT) [12]. It is known that exogenous over-expression of
STING activates type I IFN production [3], and this induction was
inhibited in the presence of the wt, but not catalytically inactive,
DENV protease [9,12]. In combination, these ﬁndings demonstrate
that NS2B/3 binds and degrades STING to inhibit IFN induction, and
that this function requires NS2B/3’s protease activity. Importantly,
although there are four antigenically distinct serotypes of DENV
(DENV-1 to -4), these observations were not limited to any
particular serotype as STING degradation was observed during
infection with DENV-1 and several different DENV-2 strains [9,12].
The consensus cleavage site for the DENV protease is located
towards the N-terminus of the 379-residue STING molecule
(94RR#GA97) [9,12], close to a cysteine-rich redox motif (88CXXC91)
that is required for STING dimerisation and the induction of type I
IFN [9,40]. Using a STING construct containing an N-terminal HA
tag and a C-terminal V5 tag, the Lin group demonstrated that the
STING cleavage products co-migrate on western blots with STING
truncation mutants designed around the predicted cleavage site
[12], suggesting that this sequence is in fact the target site for
NS2B/3. In contrast to full-length STING, neither of the truncation
mutants were functional in a reporter assay that measures the
ability of over-expressed STING to induce type I IFN [12],
conﬁrming that cleavage of STING by the DENV protease disrupts
STING functionality as an adaptor for type I IFN induction.
Interestingly, unlike the 94RR#GA97 NS2B/3 cleavage site found
in human STING (hSTING), the equivalent sequence in murine
STING (mSTING) is quite different (94HCMA97) [9,12]. Consequent-
ly, while NS2B/3 is able to interact with both human and murine
STING in over-expression experiments, only hSTING is cleaved by
the DENV protease [9,12]. When the NS2B/3 cleavage site in
hSTING is replaced with its murine counterpart, the DENV protease
loses its ability to degrade hSTING and inhibit STING function
[9,12]. In the reciprocal experiment, introducing the cleavage site
of hSTING into mSTING does not make mSTING susceptible to the
action of the DENV protease [9,12], suggesting that additional
distal sequences within STING are required for STING cleavage by
NS2B/3. These observations were initially made in over-expression
experiments in 293T and A549 cells (both human cell lines) in
which luciferase reporter activity or endogenous IRF-3 phosphor-
ylation was induced by STING over-expression [9,12]. We further
veriﬁed these ﬁndings in a more biologically-relevant context by
using Semliki Forest virus (SFV)-based protein expression vectors
to infect human MDDCs and murine bone marrow-derived DCs
[9]. In this experiment, SFV expressing the catalytically inactive
S135A protease mutant induced type I IFN to a higher degree than
SFV expressing wt NS2B/3 in human MDDCs, while similar levels of
IFN induction were observed with both SFV constructs in murine
DCs [9]. Furthermore, when we introduced wt hSTING and the
uncleavable hSTING mutant containing the murine sequence into
human MDDCs by lentivirus transduction we observed more
pronounced IFN-b induction during DENV infection, and a
concomitant reduction in viral RNA levels, with the uncleavable
hSTING mutant [9].
The development of a vaccine and antiviral therapies
against DENV has been hampered in part by the lack of an
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petent mice are refractory to DENV infection unless the virus is ﬁrst
adapted for growth in mice [41,42]. This restriction is thought to
arise due to species-speciﬁc differences in immunological restric-
tion factors [43], and potentially also in virus–host interactions
required for viral entry into cells [44]. We and others have
proposed that an immunocompetent mouse model for DENV could
be developed by humanising mice through the replacement of key
immunological restriction factors with their human counterparts
[9,12,43]. Regarding the potential utility of STING in such
transgenic mice, we observed enhanced levels of DENV replication
in Sting/ mouse embryonic ﬁbroblasts (MEFs) compared to
Sting+/+ (wt) MEFs using human strains from DENV serotypes 2,
3 and 4, as well as the mouse-adapted strain New Guinea C
[9]. Relative to human cells, we consistently observe a more robust
induction of type I IFN during DENV infection in wt MEFs and
murine bone marrow-derived DCs due to the inability of the DENV
protease to antagonise mSTING, and importantly IFN-b levels
during DENV infection were reduced in Sting/ MEFs in
comparison to Sting+/+ MEFs [9]. Taken together, these data
conﬁrm the importance of STING signalling for the induction of
type I IFN during DENV infection, as well as identifying STING as
one of the species-speciﬁc DENV restriction factors in mice.
We next went on to show that hSTING is able to functionally
replace mSTING in Sting/ MEFs [9]. Speciﬁcally, only the
uncleavable hSTING mutant, and not wt hSTING, rescued type I
IFN induction during DENV infection in Sting/ MEFs, with a
concomitant reduction in DENV replication [9]. This is because wt
hSTING, but not the uncleavable mutant, is rendered non-
functional by the DENV NS2B/3 protease. These promising
preliminary observations suggest that transgenic mice expressing
hSTING in place of mSTING might be productively infected with
non-mouse-adapted DENV strains (more relevant to human
clinical infection), while retaining their ability to mount a more
authentic immune response than current mouse models for DENV,
which are more immunocompromised. In reality it would likely be
beneﬁcial to engineer such transgenic (knock-in) mice to also
express human version of other known immunological restriction
factors, such as STAT2 [43]. If successful, these immunocompetent
humanised mouse models would be hugely beneﬁcial to the
development of vaccines and targeted therapies against DENV.
2.1.2. Synchronicity I: conservation of STING antagonism among
ﬂaviviruses
Although somewhat similar, the cleavage speciﬁcities of the
ﬂavivirus proteases are nevertheless distinct [45,46]. This becomes
of interest when considering the potential conservation of NS2B/
3’s alternative function as a STING antagonist. In fact, the Lin group
did not observe STING cleavage during JEV infection or when JEV
NS2B/3 was over-expressed in isolation [12]. Furthermore, we
were unable to detect STING cleavage with the YFV NS2B/3
(unpublished observations), although it should be noted that we
have only tested the YFV vaccine strain 17D and it is possible that
part of the attenuation in this virus is due to an altered ability of the
protease to antagonise STING. Nevertheless, YFV is known to
antagonise STING’s ability to induce type I IFN with its NS4B
protein, which binds and colocalises with STING in transient
transfection experiments [8]. Further mechanistic details remain
to be elucidated. Interestingly, we did not observe an inhibition of
type I IFN induction with the DENV-2 NS4B protein using various
stimuli in human MDDCs and in 293T cells [39]. However, we did
not test STING-speciﬁc stimuli in our assays. It is nevertheless
interesting to postulate that DENV and YFV have evolved distinct
mechanisms to antagonise STING because the different cleavage
speciﬁcities of their proteases prohibit the YFV protease from
degrading STING. It is surprising then that JEV does not cleaveSTING, especially considering that STING has been shown to be
important for orchestrating the innate immune response to JEV in
neuronal cells [47]. However, we cannot rule out that JEV has
evolved different mechanisms for blocking STING signalling, either
upstream or downstream of STING itself, or that the observations
made by Yu et al. are virus strain-speciﬁc.
Finally, STING is known to be conserved across divergent
vertebrate species [3,48,49], as well as in Drosophila [50]. It would
be highly interesting to perform a systematic comparison of
STING antagonism (and the diversity of mechanisms underlying
it) across the Flavivirus genus in the diverse vertebrate hosts and
invertebrate vectors infected by these viruses. Understanding the
functions of invertebrate STING is of particular interest because
how arboviruses are sensed, and how they might counteract
inducible immune responses, remains poorly understood in the
vector. These virus-vector immune interactions likely have a
large impact on arbovirus transmission, and understanding
them better may lead to new strategies for blocking arbovirus
transmission.
2.1.3. End of the game: STING antagonism by the hepatitis C virus
NS4B protein
Hepatitis C virus (HCV) belongs to the Hepacivirus genus within
the Flaviviridae family, and is only distantly related to the
ﬂaviviruses discussed so far [28]. World-wide, an estimated
170 million people are chronically infected with HCV, with 3–4
million new infections and more than 350,000 deaths annually
[51,52]. HCV is a blood-borne virus that primarily infects
hepatocytes [53]. The virus becomes persistent in 60–80% of
patients, eventually causing progressive liver disease, including
ﬁbrosis, cirrhosis and in some cases hepatocellular carcinoma
[51,53,54]. There is currently no licensed vaccine for HCV [55]. Up
until recently, HCV infection was treated primarily with a
combination of pegylated IFN-a and ribavirin, with a 50% success
rate, however the development of speciﬁc antivirals targeting the
HCV polymerase and protease has dramatically improved patient
outcomes [52,54]. Understanding the mechanisms by which HCV
antagonises STING is of interest because it may help explain why
the immune system spontaneously clears acute HCV infection in
some patients, but not others, as well as why viral genotype-
speciﬁc differences in the success of antiviral therapies are
observed in the clinic [54].
The HCV protease complex, consisting of the non-structural
protein NS3 and its cofactor NS4A, is well-known to disrupt the
RIG-I-dependent induction of type I IFN by cleaving MAVS at
residue 508 [reviewed in 52]. MAVS and NS3/4A colocalise at
MAMs, and following its cleavage, MAVS loses its ability to
dimerise, associate with intracellular membranes and signal the
induction of type I IFN [52]. Cheng et al. were the ﬁrst to report an
NS3/4A-independent mechanism by which HCV counteracts IFN
production [56]. In this article, inhibitors of the NS3/4A protease
were shown to block the ability of HCV to antagonise IFN-b
induced by MAVS over-expression, but not when IFN-b production
was stimulated by poly(I:C) transfection [56]. Later, two reports
published in quick succession independently demonstrated that
transiently over-expressed NS4B inhibited activation of an IFN-b
reporter stimulated with poly(I:C) [57] or by over-expression of
the constitutively active DRIG-I construct [21,58]. A concomitant
reduction in downstream IFN signalling was also observed
[58]. Importantly, these observations were not viral strain-speciﬁc
[58].
While this early work identiﬁed an important novel role for
NS4B in blocking type I IFN responses during HCV infection, it was
not until 2013 that the mechanism of this antagonism was
published. Following up on their initial ﬁndings [58], research led
by Mamoru Watanabe demonstrated that NS4B inhibits IFN-b
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treatment, or STING, MAVS or DRIG-I over-expression [10]. Ding
et al. independently made similar observations, and also showed
that NS4B blocks type III IFN induction during SeV infection
[13]. NS4B did not inhibit IFN-b production stimulated by over-
expression of IRF-3 or NF-kB, suggesting that NS4B acts upstream
of IRF-3 [13]. The NS3/4A protease complex did not block STING-
mediated IFN-b induction or IRF-3 phosphorylation [10], con-
ﬁrming that NS3/4A and NS4B antagonise IFN production by
distinct mechanisms. In addition, NS4B, but not NS3/4A, inhibited
IFN production induced by over-expression of a MAVS construct
that mimics the product of NS3/4A-mediated MAVS cleavage
[10,13]. This MAVS cleavage product loses its ability to dimerise
and localise to the mitochondrial membrane [59–61], but residual
levels of IFN-b induction are still detectable [10,13,59]. Therefore,
HCV has evolved distinct and additive mechanisms involving NS4B
and the NS3/4A protease for blocking IFN induction via RIG-I and
STING.
Importantly, STING was conﬁrmed to be important for type I
and type III IFN induction by the HCV 30 untranslated region (UTR)
[13], which contains a well-characterised PAMP recognised during
HCV infection [62]. Silencing STING by RNA interference (RNAi) or
antagonising STING by over-expressing NS4B enhanced replication
of an HCV replicon or HCV virus respectively [10]. Taken together,
these data highlight the important role STING plays in signalling
the induction of antiviral effectors that limit HCV replication.
Work by Ding et al. and the Watanabe group demonstrated that
NS4B co-immunoprecipitates with STING when both proteins are
over-expressed [10,13]. Ding et al. further veriﬁed these ﬁndings
with endogenous STING in the PH5CH8 hepatocyte cell line [13]. In
addition, colocalisation of NS4B and STING was observed when
both proteins were over-expressed [10,13], with over-expressed
NS4B and endogenous STING in PH5CH8 cells [13], and when
STING was over-expressed during HCV infection in the hepatocyte
cell line Huh7 [13]. These experiments are complicated by the fact
that HCV only readily infects Huh7 cells, in which endogenous
STING is undetectable by western blot [13]. Nevertheless, it is
encouraging that ﬁndings from over-expression experiments have
been validated with endogenous STING and during viral infection.
Colocalisation and interaction of STING with NS4B was further
veriﬁed using bimolecular ﬂuorescence complementation (BiFC),
in which the activity of a split ﬂuorescent protein (in this case
monomeric Kusabira Green; mKG) is reconstituted when two
proteins tagged with complementary mKG fragments interact in
close proximity [10]. The interaction between NS4B and STING was
shown to occur adjacent to and partially colocalised with MAMs
[10], which is also the site at which STING associates with MAVS
[8,10]. However, NS4B interacted and colocalised only with STING,
and not with MAVS [10,13].
The precise mechanism by which NS4B inhibits STING
signalling remains to be fully elucidated. Transient over-expres-
sion of NS4B does not appear to affect levels of endogenous STING
or STING dimerisation [13]. There is conﬂicting evidence as to
whether NS4B might inhibit the interaction between STING and
MAVS [10,13], and whether NS4B targets TBK1 to inhibit IFN
production [13,58]. These contradictory ﬁndings might stem from
the limitations of over-expression experiments, and until better
tissue culture models for HCV are developed it will remain
challenging to validate these studies in the context of viral
infection. Although the exact mechanism of STING antagonism
remains unclear, the N-terminus of NS4B, which shares homology
with STING’s dimerisation domain, appears to be important
[8,10]. While this domain is not important for the ability of
NS4B to colocalise with STING, it is essential for NS4B’s ability to
inhibit IFN-b induction [10]. Interestingly, this STING homology
domain is conserved in the NS4B proteins of other members of theFlaviviridae family [8], suggesting that the YFV NS4B might also
inhibit STING signalling through a mechanism that is conserved
between ﬂaviviruses and hepaciviruses. The DENV NS4B also
shares this homology domain [8]. In the future, it will be
important to further clarify the mechanism and conservation of
STING antagonism by Flaviviridae NS4B proteins. This is of
particular interest because several antiviral compounds targeting
the HCV NS4B are under development or in the early stages of
clinical testing [reviewed in 63], and it has been suggested that
they function at least in part by blocking the ability of HCV to
inhibit innate immune responses important for viral clearance
[10].
2.2. Coronaviridae
Coronaviruses are the largest RNA viruses, with non-segmented
positive-sense ssRNA genomes of up to 26–32 kb in length
[64]. The family Coronaviridae is further subdivided into the
subfamilies Coronavirinae, which we will focus on here and which
encompasses the alpha-, beta- and gammacoronaviruses (Fig. 3A),
and Torovirinae [64]. Following viral entry into the cell, the
replicase-transcriptase polyprotein is translated directly from the
viral genome by a frame-shifting mechanism (Fig. 3B) [64]. The
polyprotein is autocatalytically processed to produce 16 non-
structural proteins (nsp1-nsp16), which help form cytoplasmic
vesicles in which viral genome replication and the production of
multiple nested subgenomic mRNAs encoding the structural and
additional non-structural proteins occurs via negative-sense RNA
intermediates [64]. Viral particles are assembled at the ER-Golgi
intermediate compartment (ERGIC) and released via exocytic
vesicles [64].
Coronaviruses cause several respiratory and enteric diseases of
economic importance in domestic animals [64]. In addition, the
alphacoronaviruses human coronavirus NL63 (HCoV-NL63) and
HCoV-229E, and betacoronaviruses HCoV-OC43 and HCoV-HKU1
cause the ‘common cold’ in humans, as well as more severe disease
in young, elderly and immunocompromised patients [64]. HCoV-
NL63 in particular is associated with croup in children [64]. More
recently, coronaviruses have attracted wide-spread media atten-
tion with the zoonotic emergence of two epidemic betacorona-
viruses causing high mortality in humans; severe acute respiratory
syndrome coronavirus (SARS-CoV) in 2003 and Middle East
respiratory syndrome coronavirus (MERS-CoV) in 2012 [reviewed
in 65]. There are no speciﬁc antivirals available to treat coronavirus
infection, and no vaccines against the highly pathogenic SARS-CoV
and MERS-CoV [65,66].
Coronaviruses possess multiple mechanisms by which they
evade the host innate immune response [67,68], and it has been
suggested that this immune evasion may contribute to severe
coronavirus disease [69]. In addition, a better understanding of
coronavirus immune evasion tactics may facilitate the develop-
ment of antiviral therapies and vaccines. We will focus here on the
recently characterised mechanism of STING antagonism by
coronaviruses.
2.2.1. Wrapped around your ﬁnger: STING antagonism by the SARS-
CoV papain-like protease
Coronavirus PLPs are contained within the nsp3 protein (Fig. 3C
and D) and, along with the nsp5-encoded 3C-like protease, they are
responsible for cleaving the replicase-transcriptase polyprotein
[64,68]. Antagonism of STING by coronavirus PLPs has been most
extensively studied for the SARS-CoV PLP, called PLpro. SARS-CoV
was ﬁrst identiﬁed in China in 2003 and rapidly spread around
Southeast Asia, with isolated cases reported around the globe
[65,68]. The virus is thought to have originated from bats, with
palm civet cats as a potential intermediate host that transmitted
Fig. 3. Coronavirinae phylogenetic tree, genome organisation, and nsp3 functional domains. (A) Coronavirinae family tree. Viruses of relevance to this review, and other
representative viruses, shown. (B) SARS-CoV genome organisation (not to scale). Structural proteins are in black. The two polyproteins (1a and 1ab) translated by ribosomal
frameshifting are shown. Triangles indicate PLpro cleavage sites; the remaining polyprotein cleavage sites are processed by the main 3C-like protease. The 30 structural and
additional accessory proteins differ among coronaviruses. Functional domains encoded by the SARS-CoV (C) and the HCoV-NL63 (D) nsp3 are also shown (not to scale).
Domains linked to STING antagonism are highlighted in grey; the precise function of the transmembrane (TM) domain remains unknown. Terms not deﬁned elsewhere; TCoV,
turkey coronavirus; IBV, infectious bronchitis virus; Ubl, ubiquitin-like domain; Ac, acidic domain; ADRP, poly(ADP-ribose)-binding/ADP-ribose-10-phosphatase
macrodomain; NAB, nucleic acid-binding domain; G2M, betacoronavirus marker; Y domain, highly conserved coronavirus domain.
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[65]. SARS-CoV was an air-borne pathogen that caused a severe
lower respiratory tract infection with an estimated case-fatality
rate of around 10% [64,65,68]. The epidemic spread from Southeast
Asia via international air travel and trade, and was contained
largely by strict quarantine and travel restrictions [65]. More than
8000 SARS cases were reported in 2003, and since then no further
human infections have been reported [65]. Nevertheless, the
pertinence of studying the pathogenic mechanisms of this severe
respiratory pathogen was highlighted when MERS-CoV emerged in
the Arabian peninsula in 2012 [65].
The ability of SARS-CoV PLpro to block type I IFN production
was ﬁrst reported by Devaraj et al. in 2007, when PLpro was shown
to inhibit IRF-3 phosphorylation, dimerisation and nuclear
translocation, and IFN-b induction in HeLa cells stimulated with
poly(I:C) or SeV [70]. Interestingly, this IFN antagonism was
independent of PLpro’s catalytic activity, as several inactive PLpro
mutants were still able to block IFN-b promoter activation with
varying efﬁciencies [70]. Unless speciﬁed, these and subsequent
studies described herein were performed with constructs encom-
passing just the PLP and its transmembrane domain, distinguishing
between PLP function and nsp3’s other activities.Subsequent reports linking the ability of PLPs to inhibit type I
IFN induction with their ability to antagonise STING all originate
from the lab of Zhongbin Chen [11,14,15]. Initially, PLpro was
shown to inhibit the activation of an interferon-stimulated
response element (ISRE)-linked luciferase reporter stimulated by
the exogenous over-expression of STING [11]. In line with previous
reports [70,71], PLpro still retained some ability to antagonise
STING-mediated IFN induction when its catalytic activity was
inactivated by point mutation [11].
PLpro was then shown to co-immunoprecipitate with STING
when both proteins where over-expressed, and this interaction
was also observed with catalytically inactive PLpro mutants
[11]. In a follow-up paper, the STING-PLpro association was found
to be dependent on the four N-terminal transmembrane domains
of STING [14]. However, whether this region actively facilitates
STING-PLpro binding or whether it is only necessary for localisa-
tion of STING to intracellular membranes, presumably required for
interaction with membrane-bound PLpro, remains unclear, as
deletion of either transmembrane domains 1 and 2, or 3 and 4 did
not affect STING-PLpro binding [14].
Importantly, the interaction between PLpro and STING was
found to inhibit STING function. Dimerisation of over-expressed
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the presence of PLpro [11]. Additionally, dimerisation of over-
expressed STING was reduced during SARS-CoV infection [11]. Lat-
er, PLpro was also found to disrupt the formation of signalling
complexes involved in the induction of type I IFN [14]. Speciﬁcally,
PLpro co-immunoprecipitated with over-expressed TBK1 and (to a
lesser extent) IRF-3, and also inhibited the binding of STING to
MAVS and IRF-3 [14]. In addition, PLpro dramatically inhibited the
activation of luciferase reporter constructs driven by the IFN-b
promoter or IRF-3-responsive elements when these were induced
through the over-expression of STING or TBK1 [14]. IRF-3
phosphorylation and dimerisation induced by STING or TBK1
over-expression was also reduced in the presence of PLpro [14]. In
combination, these ﬁndings demonstrate that PLpro associates
with the signalling complexes assembled around STING, disrupting
their formation to block downstream signalling via IRF-3. It
remains to be determined whether PLpro interacts with STING
directly, or whether other components of the signalling complex
are required. However, other viral proteins are not necessary for
mediating the interaction between PLpro and STING [11,14].
It has been proposed that PLpro inhibits IRF-3 activation by
virtue of its deubiquitinase (DUB) activity, interfering with K63-
linked ubiquitination events known to be important for down-
stream type I IFN induction [11,14]. Initially, X-ray crystallography
studies highlighted structural similarities between PLpro and
cellular DUBs [72]. Subsequently, puriﬁed PLpro was shown to
hydrolyse K48- and K63-linked polyubiquitin chains, as well as the
ubiquitin-like molecule ISG15, in vitro [73–75]. Deubiquitinating
activity was also observed in cultured cells [71,73,75]. Of note, the
modiﬁcation of over-expressed STING, TBK1, RIG-I and IRF-3 with
an HA-tagged ubiquitin construct that is only capable of forming
K63-linked bonds (HA-Ub-K63) was also reduced in the presence
of PLpro [14]. Surprisingly then, chemical inhibitors of PLpro’s DUB
activity do not affect PLpro’s ability to antagonise type I IFN
induction [71]. Furthermore, inactivation of PLpro’s DUB domain
by point mutation failed to abrogate its ability to block IFN-b
induction by SeV [70]. A confounding factor in these experiments is
that the importance of functional DUB activity was not always
measured in the presence of STING-speciﬁc stimuli. Therefore
DUB-inactive PLpro may inhibit type I IFN induction by a STING-
independent mechanism, for example by targeting IRF-3 directly
[70]. In addition, the Chen group has proposed that, in the absence
of a functional DUB domain, PLpro is still able to block K63-linked
polyubiquitination of STING signalling complex components by
preventing access to the cellular ubiquitination machinery
[11,71,76]. Alternatively, since catalytically inactive PLpro mutants
still interact with STING [11], they may function by sequestering
STING away from other molecules required for the induction of
type I IFN. While the precise mechanism of action remains to be
fully elucidated, an increasing body of work has clearly demon-
strated that the SARS-CoV PLpro protein interacts with STING to
prevent its dimerisation and association with other signalling
molecules required for the activation and nuclear translocation of
IRF-3.
2.2.2. Synchronicity II: conservation of STING antagonism among
coronavirus papain-like proteases
Unlike SARS-CoV, most alpha- and betacoronaviruses encode
two PLPs within their nsp3 protein (Fig. 3D) [64]. Interestingly,
Clementz et al. demonstrated that one of the PLPs of the
alphacoronavirus HCoV-NL63, PLP2, which, like SARS-CoV PLpro,
is encoded at the C-terminal end of nsp3, also possesses DUB
activity [71]. PLP2 was also shown to inhibit type I IFN production
[71]. The Chen group later conﬁrmed that PLP2 antagonises
STING-induced IRF-3 nuclear translocation and ISRE activation
[11].Despite the low sequence conservation between SARS-CoV
PLpro and HCoV-NL63 PLP2 [75], the mechanism of action of these
two proteins appears to be very similar. PLP2 was shown to co-
immunoprecipitate with STING in over-expression experiments,
and this interaction was independent of PLP2’s catalytic activities
[11]. Furthermore, exogenously expressed PLP2 colocalised with
STING in a pattern reminiscent of the ER [11]. A partial
colocalisation between nsp3, which contains the PLP2 domain,
and over-expressed STING was also observed in cells infected with
HCoV-NL63 [11]. Importantly, PLP2 was shown to disrupt STING
dimerisation, as well as the interaction between STING and TBK1 in
over-expression experiments [11]. Interestingly, the DUB activity
of HCoV-NL63 was found to be important for the inhibition of
STING dimerisation [11]. Whether DUB activity is also important
for the ability of SARS-CoV PLpro to inhibit STING dimer formation
has not been published. Similarly to SARS-CoV PLpro though, the
K63-linked polyubiquitination of STING was still inhibited in
HCoV-NL63 PLP2 mutants that lacked DUB activity, albeit to a
lesser degree [11]. As before, the authors speculated that STING-
PLP2 binding may prevent the cellular ubiquitination machinery
from modifying STING, regardless of whether PLP2 retains its
ability to actively deubiquitinate STING [11]. Since certain PLP2
mutants that lack DUB activity are still capable of blocking STING-
dependent IFN production, even though they do not prevent STING
activation (dimerisation), these constructs may function by
sequestering STING away from other proteins required for the
induction of type I IFN [11].
The PLP2 protein of the alphacoronavirus porcine epidemic
diarrhoea virus (PEDV) has also been shown to inhibit the STING-
dependent activation of the IFN-b promoter and IRF-3-dependent
reporters [15]. PEDV PLP2 also co-immunoprecipitates with STING
in over-expression experiments, and reduces the modiﬁcation of
STING with K63-linked polyubiquitin chains [15]. However, unlike
the coronavirus PLPs discussed so far, the ability of PEDV PLP2 to
inhibit STING ubiquitination and type I IFN induction appears to be
dependent on its DUB activity [15]. The authors speculated that,
since the PLP constructs in the PEDV study differ from the others in
that they are not linked to the C-terminal transmembrane domain
of nsp3, the transmembrane domain may somehow modify PLP
function [15]. In fact, the transmembrane domain was previously
shown to augment IFN antagonism by both wt and catalytically-
inactive HCoV-NL63 PLP2 [71]. It was proposed that the
transmembrane domain may be required for the correct folding
of PLP2 or for mediating interactions with components of the IFN
pathway [71]. Therefore, while it is becoming increasingly clear
that several coronavirus PLPs antagonise STING, certain mecha-
nistic details, including the roles of the DUB and transmembrane
domains, remain to be elucidated.
Whether the STING antagonist function of PLPs is conserved in
all coronaviruses is unknown. Work led by Zhongbin Chen recently
identiﬁed DUB activity in MERS-CoV PLP2, which was also shown
to inhibit IRF-3 phosphorylation and nuclear translocation, and
activation of the IFN-b promoter [76]. In addition, the PLP2 of the
betacoronavirus murine hepatitis virus A59 (MHV-A59) has also
been shown to have DUB and IFN antagonist activity
[77,78]. Whether MERS-CoV PLP2 and MHV-A59 PLP2 block type
I IFN induction by targeting STING remains to be determined. It
would be highly interesting to perform a systematic comparison of
STING antagonism in different coronavirus PLPs using human
STING as well as STING homologues from the animal reservoirs for
these viruses. Such experiments would provide valuable insights
into the evolutionary pressure posed by STING, the adaptations
required for coronaviruses to emerge as zoonotic pathogens of
humans, and the potential contribution of STING antagonism to
disease severity in highly pathogenic coronaviruses. Such studies
have gained in pertinence with the emergence of MERS-CoV as the
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tial in humans.
3. Fields of gold: ﬁnal thoughts and key questions for future
research
STING has emerged as an important player in the cell’s arsenal
against RNA viruses. While we do not yet fully understand all of the
mechanisms by which STING participates in the recognition of RNA
virus infection, the multiple evasion tactics employed by divergent
positive-sense RNA viruses imply that STING is a signiﬁcant
restriction factor for these pathogens. Exciting avenues for future
research include the as-yet poorly deﬁned mechanisms by which
STING signalling is triggered during RNA virus infection. It will be
highly interesting to investigate whether STING responds to RNA
and DNA viruses via similar or distinct mechanisms. An intriguing
possibility is that STING senses RNA viruses independently of the
well-characterised nucleic acid PAMPs studied to-date, for
example by responding to the aberrant modiﬁcation of cellular
membranes. Another key question regards the importance of
STING in sensing and restricting negative-sense RNA virus
infection. While improving our understanding of the mechanisms
of STING activation during RNA virus infection will go some way
towards answering this question, the clinching evidence will be to
identify a STING antagonist in a negative-sense RNA virus, as
viruses do not develop immune evasion mechanisms without a
strong evolutionary imperative to do so.
In terms of ﬂavivirus evasion of STING signalling, it will be
important to address the evolutionary conservation of the various
mechanisms of STING antagonism identiﬁed to-date. It will also be
highly interesting to further explore the role STING plays in the
host restriction of ﬂaviviruses, and the putative roles STING
homologues might play in the insect vectors of arboviral
ﬂaviviruses. Such studies will provide valuable insights into the
potential for novel ﬂaviviruses to emerge as human pathogens of
the future, as well as potentially identifying new approaches for
developing much-needed vaccines and antiviral therapeutics. For
DENV, assessing the feasibility of using mice humanised for STING
as immunocompetent animal models is of utmost importance to
improve our understanding of DENV pathogenesis in vivo, and for
testing vaccines and antiviral compounds.
For coronaviruses, the precise mechanism of STING antagonism
remains to be clariﬁed. It will also be important to deﬁne the
contribution STING antagonism makes to the pathogenic potential
of coronaviruses. The conservation of STING evasion among
coronaviruses, and the role STING might play in restricting
coronavirus host-switching are also exciting research avenues,
especially given the emergence of two highly pathogenic
coronaviruses in just over a decade.
The ﬁeld of STING sensing of, and antagonism by, RNA viruses is
still in its infancy, and the many important unanswered questions
of relevance to diverse aspects of viral pathogenesis make this an
exciting time to be working on this new player in the innate
immune sensing of RNA viruses.
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